Pressure-test the science behind your next decision.
Bring one decision — in the science, in the deal, or both. We test the story behind it: what the data support, what’s premature, what a partner will challenge, and which experiment would most change the answer.
The same evidence discipline anchors our published, citable research — deposited reports and essays that carry registered DOIs.
Strategic Scientific Hypothesis Engagement
A focused advisory deliverable that starts from the data a team already has, identifies the mechanistic gaps that matter most, and prioritizes the experiments or readouts that would most strengthen the scientific story, investor narrative, and development strategy. It clarifies what is defensible now, what remains uncertain, and how different results would change development, partnering, IP, funding, trial design, or platform positioning.
Best for
- Platform claim pressure test
- Mechanism-to-experiment roadmap
- Indication, combination, or sequencing strategy
- Phase 1 biomarker and translational readout planning
- Investor, partner, or board scientific framing
- Metabolic and cross-organ strategy questions
Deal & Partnering Strategy
The science being right is half the decision — the deal being right is the other half. Led by a partner who is an operating biopharma executive and a transactional attorney, we help teams structure, negotiate, and protect partnerships, licensing, and financing — so the value created in the lab is not given away at the table.
Where it helps
- Deal structure and term review
- Partnership and licensing negotiation
- Protecting founder equity and terms
- Cross-border partnering (incl. China)
- NDAs, letters of intent, entity structure
- Transaction readiness before a partner or financing process
A written deliverable you can act on — and hand to a partner
Every engagement produces an evidence-graded written analysis — structured so the next decision is clear.
An evidence-graded analysis
Every load-bearing claim mapped to its evidence and graded well-supported, plausible, premature, or unsupported.
A competitive mechanism landscape
Where the asset sits scientifically against the field, by mechanism and evidence, not market share.
Convened expert / KOL input
The questions the field’s key opinion leaders raise, engaged and synthesized for your specific question.
The gaps a partner will flag
The specific questions an investor’s or partner’s diligence team would raise, surfaced before they do.
The experiments worth running
A ranked list of the 3–5 readouts that would most change the decision, split into deal-breaker and nice-to-have.
A partner-facing summary
A one-page scientific summary you can put in front of a prospective partner or investor the same week.
Deal & partnering readiness
How the science shapes deal timing, structure, and protections, with partner-led transaction judgment (NDAs, letters of intent, entity and partnership structure).
Delivered as a presentation deck or a written analysis — or a focused working session — matched to the decision and who needs to act on it.
The illustrative sample hypothesis engagement
A Series-A team positioning an oral incretin asset for a pharma partnership asked what a partner’s diligence would challenge. This deck shows the engagement — the load-bearing claims graded, then the three falsifiable, mechanism-first hypotheses that decide the thesis, each with the experiment that settles it and a decision tree of what every outcome means. An invented asset, no real client.
View the sample deliverable (PDF) →
Scoped, confidential, deliverable-driven
Every engagement starts with a confidential scoping conversation and a short written scope — the question, sources, timeline, and output agreed up front, organized around a clear deliverable.
Scope the decision
Clarify the strategic question, decision context, and intended use of the deliverable.
Map the current evidence
Review the data, publications, patents, competitive context, and relevant market or development signals.
Identify the strategic gaps
Separate what is supported, what is plausible, what is premature, and what an investor, partner, board, or development team would likely challenge.
Prioritize the experiments or readouts
Identify the experiments, biomarkers, analyses, or translational readouts that would most improve the strategic case.
Build the deliverable
Synthesize the implications into a clear deliverable, deck, or working session: what can be claimed now, what should be tested next, and how different outcomes would change the strategy.
The questions that decide whether broader value is captured or missed
Whatever seat you’re in, we start from the decision in front of you.
Have a scientific strategy question?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? [email protected]